Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Site Reviewer Perspectives on Implementation of Commission on Cancer Operative Standards
Kravchenko, Timothy , Funk, Elizabeth C, Francescatti, Amanda B. , Hendren, Samantha , Boffa, Daniel J. , Dossett, Lesly A. , Baskin, Alison S. , Funk, Elizabeth C, Hieken, Tina J. , Boughey, Judy C. , Weigel, Ronald J.

Journal of the American College of Surgeons | July 8, 2025 | Volume: 242 | Issue: 1 | Pages: 113-125

10.1097/xcs.0000000000001462 | PMID 40626591 Get It

BACKGROUND: To reduce technical variation in cancer surgery, the Commission on Cancer (CoC) recently implemented 6 operative standards as part of its national cancer center accreditation process. CoC sites are evaluated for compliance with these standards through scheduled visits conducted by trained site reviewers. We characterized site reviewers’ perspectives on the implementation of the operative standards. STUDY DESIGN: Twenty interviews were conducted with CoC site reviewers using a semistructured interview guide based on the Reach, Effectiveness, Adoption, Implementation, and Maintenance framework. Themes were identified using thematic analysis mapped to the updated Consolidated Framework for Implementation Research. RESULTS: Site reviewers viewed the operative standards as an effective starting point for improving technical quality and were optimistic the standards would lead to positive change. Compliance was associated with supportive site leadership, effective interdisciplinary communication, and the availability of adequate personnel and institutional resources. In contrast, resistance from surgeons was identified as a key barrier. CoC site reviewers interpret their role as extending beyond assessing compliance, viewing themselves as advocates, educators, and partners to the sites. CONCLUSIONS: Overall, CoC site reviewers perceive the operative standards favorably. To enhance implementation of the operative standards, efforts should focus on modifiable institutional and individual-level factors, such as leadership support and surgeon engagement. Additionally, the multifaceted role of the site reviewers presents a valuable opportunity to improve compliance by formalizing the supportive relationship between reviewers and sites.
Peptide receptor radionuclide therapy: a new era of radiation nephropathy
Das, Abhirami, Manohar, Sandhya , Kendi, Ayse Tuba, Manohar, Sandhya , Das, Abhirami, Kendi, A. Tuba

Nephrology Dialysis Transplantation | July 8, 2025 | Volume: 41 | Issue: 2 | Pages: 220-232

10.1093/ndt/gfaf121 | PMID 40637735 Get It

ABSTRACT Peptide receptor radionuclide therapy (PRRT) has transformed the management of neuroendocrine tumors and other malignancies by enabling targeted radiation delivery while minimizing systemic toxicity. However, incidental renal radiation exposure presents a significant risk of radiation nephropathy, and this risk varies based on the unique characteristics of the radionuclide and its decay phenomenon as well as the peptide being utilized. This review explores the historical development of PRRT, the physics of radionuclide therapy as necessary for a practicing nephrologist, and key mechanisms of radiation-related kidney injury. We detail renal handling of radionuclides, dose thresholds and pathological features of PRRT-induced nephropathy. Furthermore, we discuss both current and prospective strategies to reduce renal toxicity—such as amino acid infusions, receptor saturation, cleavable linkers and emerging protective agents. Special considerations for PRRT in patients with chronic kidney disease and those on dialysis are highlighted. As PRRT applications expand, multidisciplinary collaboration is essential to optimize renal safety.
Revisiting Centiloids using AI
Bourgeat, Pierrick , Xia, Ying , Feizpour, Azadeh , Zisis, Georgios , Goyal, Manu S. , Tosun, Duygu , Short, C, Adam, Robert , Robertson, Joanne, Park, Denise C. , Farrar, Gill , Bollack, Ariane , Landau, Susan , Koeppe, Robert, Morris, John, Weiner, Michael, Villemagne, Victor L. , Masters, Colin, Doré, Vincent , Xia, Ying , Feizpour, Azadeh , Goyal, Manu , Tosun, Duygu , Benzinger, Tammie L S , LaMontagne, Pamela , Sperling, Reisa Anne , O'Bryant, Sid , Johnson, Sterling C. , Jack, Clifford R , Schwarz, Christopher G , Park, Denise C , Collij, Lyduine , Rowe, Christopher Cleon , Doré, Vincent , Bourgeat, Pierrick , Fripp, Jürgen , Lebrat, Léo , Cox, Timothy O. , Gillman, Ashley , Benzinger, Tammie L.S. , Breakspear, Michael J , Lupton, Michelle K. , Short, Cathy, O’Bryant, Sid E. , Jack, Clifford R. , Schwarz, Christopher G. , Barkhof, Frederik , Masters, Colin

No container title available | July 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7015694/v1 | PMID 40671806 Get It

Abstract The Centiloid scale is the standard for Amyloid (Aβ) PET quantification, widely used in research, clinical settings, and trial stratification. However, variability between tracers and scanners remains a challenge. This study introduces DeepSUVR, a deep learning method to correct Centiloid quantification, by penalising implausible longitudinal trajectories during training. The model was trained using data from 2,098 participants (6,762 Aβ PET scans) in AIBL/ADNI and validated using 15,806 Aβ PET scans from 10,543 participants across 10 external datasets. DeepSUVR increased correlation between tracers, and reduced variability in the Aβ-negatives. It showed the strongest association with cognition, highest AUC against visual reads and best longitudinal consistency between studies. DeepSUVR also increased the effect size for detecting lower Centiloid increase per year in the A4 study. DeepSUVR advances Aβ PET quantification, outperforming standard approaches, which is particularly important for consistent decision making and to detect subtle and early changes in clinical interventions.
Variability in Placebo Response Across Biologic and Small Molecule Classes in Induction Randomized Controlled Trials for Ulcerative Colitis: A Systematic Review and Meta-Analysis
Adam, Mohammad, Elmustafa, Fatima , Ali, Yasmin O. , Dafaallah, Miqdad, Ismail, Abdellatif , Abdelatif, Amro, Osman, Ali , Karna, Rahul , Mohamed, Mouhanad, Abushamma, S, Kaur, Harpreet, Dafaallah, Miqdad, Refaat, Mohamed, Karna, Rahul , Bilal, Mohammad , Abdallah, Mohamed, Abushamma, Suha

No container title available | July 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7050637/v1 Get It

Abstract Background: Placebo response is crucial in interpreting treatment efficacy in ulcerative colitis (UC) trials. While it has been broadly studied, it remains underexplored in trials involving the growing number of biologics and small molecules for ulcerative colitis. Methods: We systematically searched PubMed, Embase, Scopus, Web of Science, and Cochrane CENTRAL from inception to November 13, 2024. Eligible studies were induction-phase RCTs, including adult patients with moderate-to-severe UC who received a biologic and a small-molecule against a placebo. Primary outcomes were pooled clinical and endoscopic response and remission rates. Safety outcomes included adverse events (AEs), serious adverse events (SAEs), and withdrawal rates. Random-effect models were used for meta-analysis. Meta-regression identified predictors of placebo outcomes. Results: 26 induction RCTs with 3,937 placebo-treated patients were included. IL inhibitor trials had the highest placebo clinical response (36%) and endoscopic remission (21%), while JAK inhibitors had the lowest (21% and 2%). Overall placebo rates were 34% for clinical response, 8% for clinical remission, 19% for endoscopic response, and 11% for endoscopic remission. Adverse events occurred in 54%, SAEs in 8%, and withdrawals in 18%. Younger age and longer follow-up were linked to higher placebo responses; recent trials showed reduced endoscopic effects. Conclusion: These findings highlight the need to account for placebo variability in trial design and interpretation, particularly as biologic and small-molecule therapies continue to expand in UC treatment.
Sex‐Dependent Circadian Rhythm Impact on Murine Gastrointestinal Transit
Bellampalli, Shreya S. , Fonar, Gennadiy , Grynyshyn, Michael, Mercado‐Perez, Arnaldo , Farrugia, Gianrico , Matveyenko, Aleksey V. , Linden, David R. , Beyder, Arthur , Muchhala, Karan H, Linden, D R , Beyder, Arthur , Muchhala, Karan H.

Neurogastroenterology & Motility | July 8, 2025 | Volume: 37 | Issue: 12 | Pages: No page available

10.1111/nmo.70114 | PMID 40626374 Get It

ABSTRACT Background The circadian rhythm regulates gastrointestinal motility. In humans and preclinical models, such as rodents, whole gut transit (WGT) is slower during the rest phase compared to the active phase. Investigators typically study GI transit in rodents during the day, which is their rest phase, rather than during the night, which is their active phase. A circadian rhythm reversal in which mice are in a dark room during the working day (reverse light) allows studies on nocturnal animals during their active phase and has been previously shown to reduce WGT time. GI motility is often disrupted in individuals with disorders of gut–brain interaction (DGBI), which are female predominant. However, the effect of circadian rhythm on regional transit and sex dependence of the differences is not known, as most motility studies looking at circadian rhythm reversal are done in male mice. Methods We tested C57BL/6 wild‐type male and female mice in rest (12 h of light during the day) and active (reverse cycle for 2 weeks: 12 h of dark during the day) phases. We noted female estrous cycle by visual inspection. We performed carmine WGT by monitoring time‐lapse videos of pellet production. We performed fluorescence imaging of excised intestines 30 min after gavage to assess percent fluorescence for each GI region and then examined small intestinal transit (SIT) by measuring geometric center and leading edge. For colonic transit, we monitored bead expulsion time from distal colon to anus. Key Results Compared to rest phase, in the active phase, like male mice, female mice had (1) faster WGT, (2) increased frequency of pellet expulsion in the first 3 h of transit, (3) and greater total pellet production. Both male and female mice in their active phase exhibited (4) more contrast emptied from the stomach and they had (5) further leading edge of fluorescence and (6) geometric center, in SIT, and (7) faster colonic bead expulsion times. There were no significant sex differences in the active phase of WGT. In SIT, male mice had further leading edge in the rest phase than female mice, but this difference was not seen in the active phase, and in colonic transit, male mice in both the active and rest phases had faster bead expulsion than female mice. Conclusions Mice in the active phase have faster regional transit in small and large bowel than mice in the rest phase that collectively contributes to faster WGT times in the active phase of both male and female mice. These findings highlight the importance of circadian biology in sex‐dependent rodent GI transit.
Therapeutic Treatment Planning for Sex Therapy Using the Sexual Health and Integrative Pleasure (SHIP) Model
Connor, Jennifer J. , Arenella, Katherine , Oliveira, Leonor de , Evenson, LynAnne, Mark, Kristen P. , Newstrom, Nicholas P. , Robinson, Beatrice “Bean” E., Vencill, Jennifer A. , Girard, Abby , Connor, Jennifer Jo

Journal of Sex & Marital Therapy | July 8, 2025 | Volume: 51 | Issue: 6 | Pages: 629-638

10.1080/0092623x.2025.2531161 | PMID 40625285 Get It

Eptinezumab for migraine prevention after other treatments fail: a plain language summary of publications
Torre, Elena Ruiz de la , Pickering, Line , Starling, Amaal J. , Boserup, Line Pickering , Ashina, Messoud , Ettrup, Anders

Pain Management | July 8, 2025 | Volume: 15 | Issue: 8 | Pages: 453-466

10.1080/17581869.2025.2514425 | PMID 40625230 Get It

Association of Incident Dialysis Modality With Patient Survival: A Systematic Review and Meta-analysis
Zubidat, Dalia , Sikharulidze, Anna, Cicero, Elisa, Podestà, Manuel Alfredo , Castellano, Giuseppe, Nardelli, Luca , Passerini, Matteo , Sikharulidze, Anna, Alfieri, Carlo , Castellano, Giuseppe , Murad, M. Hassan

No container title available | July 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6873929/v1 Get It

Abstract Background Although the choice of dialysis technique is based on several factors, patient survival is undoubtedly one of the most relevant. In a context where randomization to either peritoneal dialysis (PD) or hemodialysis (HD) proved to be extremely challenging, previous meta-analyses were greatly limited due to the inclusion of historical studies. Methods We performed a systematic review by searching multiple databases up to April 22nd, 2022. The primary outcome was the association between dialysis modality (PD vs HD) and mortality assessed via hazard ratios (HR). Subgroup analyses were conducted to explore potential sources of heterogeneity, including sex, age, diabetes, dialysis vintage, geographical location, HD access, and study cohort inclusion period. Results Database search yielded 5317 citations, from which, 27 observational studies met the eligibility criteria, including 1 033 362 incident dialysis patients. The pooled mortality HR for PD versus HD was 1.01 (95% CI 0.93–1.10). Heterogeneity was substantial ( I 2 = 94%) and was largely explained by different baseline features of the included populations. A statistically significant subgroup effect was demonstrated for age (> 65 vs.<65 years; p = 0.01), geographical location of the studies (Oceania vs. Europe vs. Asia vs. North America; p < 0.01), and HD vascular access (central venous catheter vs. arteriovenous fistula; p < 0.01, only one study included). Conclusions This meta-analysis suggests that overall PD and incentre HD likely carry equivalent survival benefits. However, differences were detected among subgroups based on age, geographic location, HD access type, but not on sex, diabetes status, dialysis vintage and study cohort inclusion period.
An international inter‐rater agreement study in the challenging diagnosis of squamous dysplasia of the oesophagus
Patil, Ameya , Jiezhen, Tracy Loh, Kosiorek, Heidi , Brown, Ian , Carneiro, Fátima , Gill, Anthony J. , Kumarasinghe, Priyanthi , Kushima, Ryoji , Sheahan, Kieran , Shepherd, Neil A. , Slavík, Tomáš , Lauwers, Gregory Y. , Langner, Cord , Pai, Rish K. , Brown, Ian S , Kumarasinghe, Priyanthi M , Srivastava, Amitabh , Lauwers, Gregory Y , Langner, Cord , Pai, R K , Kosiorek, Heidi E , Srivastava, Amitabh

Histopathology | July 8, 2025 | Volume: 87 | Issue: 4 | Pages: 573-583

10.1111/his.15509 | PMID 40625062 Get It

AimsThere is a lack of published literature on the diagnostic reproducibility of oesophageal squamous dysplasia using a two‐tiered grading system.Methods and resultsWe identified 75 oesophageal biopsies, which were reviewed by 10 international pathologists twice (1500 total observations) with a > 4‐week washout period. Between rounds, a consensus meeting refining diagnostic criteria was held and an atlas was created to provide illustrations. Overall agreement was fair with kappa of 0.35 and 0.32 in round 1 and 2, respectively. Agreement was moderate to fair for negative for dysplasia (ND) (round 1 = 0.41 and round 2 = 0.34) and poor for indefinite for dysplasia (IND) and low‐grade dysplasia (LGD) (kappa <0.2). Agreement for high‐grade dysplasia (HGD) was good in both rounds (round 1 = 0.64; round 2 = 0.61). In round 1, majority diagnosis (MDx, ≥6 of 10 raters agreeing) was seen in 51 (68%) cases with the majority classified as ND (N = 27) or HGD (N = 18). MDx was rarely achieved for LGD (N = 6). In round 2, MDx was seen in 49 (65%) cases (20 ND, 1 IND, 11 LGD and 17 HGD). Of the 40 cases with MDx for both rounds, 39 were concordant (15 HGD, 6 LGD and 18 ND).ConclusionsOverall agreement among pathologists in diagnosing squamous lesions is fair; however, HGD had good agreement. This study fills an important gap in our knowledge of the inter‐rater variability in the diagnosis of oesophageal squamous dysplasia.